Unique Real-Time Drug Monitoring System Titan Enterprises
Titan Enterprises reports on its involvement in the development of a unique disposable flow sensor for CRISI Medical Systems (San Diego, USA), a subsidiary of Becton, Dickinson and Company (BD).
Titan Enterprises assisted CRISI in the early days of development of the unique flow sensor used in the BD Intelliport™, a medication management system for manual intravenous (IV) bolus injections. After testing an Atrato ultrasonic flowmeter, CRISI took the basic design, and with help from Titan, miniaturized the flowmeter assembly and made it into a disposable unit. Titan has granted exclusive global rights to BD for use of their Atrato technology in IV bolus injections.
BD and CRISI entered into an exclusive partnership in June 2013 to jointly develop the BD Intelliport Medication Management System, a first-of-its-kind medication management solution for manual IV bolus injections. The Intelliport system is the first and only solution to provide real-time drug identification, dose measurement and allergy detection at the point of injection while wirelessly sending captured information directly into the patient’s electronic medical record (EMR) following medication administration. The Intelliport system received clearance from the FDA in December 2014 and is expected to be commercially available in spring 2015.
Titan Enterprises Atrato ultrasonic flowmeter is a true inline non-invasive flow meter without the contorted flow path and disadvantages of alternative designs. It can handle flows from laminar to turbulent and is therefore largely immune from viscosity. It also offers excellent turndown, linearity and repeatability. Available in 60 °C and 110 °C temperature versions and a 30 bar higher pressure model, Atrato flowmeters use patented 'time-of-flight' ultrasonic technology that enables it to operate over very wide flow ranges (200:1) with excellent accuracy (better than ±1.0% of reading).
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.